Velomedix Closes $10.2M Series B
February 8, 2012
Velomedix Inc. , a Menlo Park, Calif.-based medical device company focused on therapeutic Hypothermia, has raised $10.2 million in Series B financing. In conjunction with the financing, the company also named Jeffrey Gold as chief executive officer and Michael Moore as the vice-president of operations. Details of the financing were not released
See more here:
Velomedix Closes $10.2M Series B
Synchroneuron Closes On $6M
February 7, 2012
Synchroneuron Inc. , a Waltham, Mass.-based biopharma company, has raised $6 million in Series A financing from Morningside Technology Ventures Ltd. The company is focused on therapies for movement disorders. PRESS RELEASE Synchroneuron Inc., a privately-held biopharmaceutical company, today announced the completion of its Series A financing with a $6 million investment from Morningside Technology Ventures Ltd. Synchroneuron is engaged in developing new therapies for tardive dyskinesia (TD) and other related movement disorders.
Follow this link:
Synchroneuron Closes On $6M
Synchroneuron Closes Series A with $6 Mln from Morningside Technology Ventures
February 6, 2012
Morningside Technology Ventures has invested $6 million in Synchroneuron , which said Monday that it has closed its Series A financing. Synchroneuron develops new therapies for tardive dyskinesia (TD) and other related movement disorders. PRESS RELEASE Synchroneuron Inc., a privately-held biopharmaceutical company, today announced the completion of its Series A financing with a $6 million investment from Morningside Technology Ventures Ltd. Synchroneuron is engaged in developing new therapies for tardive dyskinesia (TD) and other related movement disorders. The company was founded by inventor and neurologist Dr
Read the original:
Synchroneuron Closes Series A with $6 Mln from Morningside Technology Ventures
United Silver and Hale Capital Partners Complete $6M Financing
February 2, 2012
United Silver Corp ., a mining company based in Vancouver, has finalized its agreement with New York-based private equity firm Hale Capital Partners , which has issued USC $6 million in secured convertible notes. Proceeds of the loan will be used for working capital and general corporate purposes. PRESS RELEASE: United Silver Corp.
Go here to see the original:
United Silver and Hale Capital Partners Complete $6M Financing
Regulators warn Seattle’s P.I. Bank
January 27, 2012
Regulators have told Pacific International Bank to appoint a qualified CEO and increase a capital cushion it keeps to make up for loan losses, among other things, according to an announcement Friday from the Federal Deposit Insurance Corporation. The FDIC also told the bank to reduce its concentration in loans in the commercial real estate sector, especially those with borrowers in the hotel or gas station industry. I put a call in to Seattle-based P.I. Bank’s interim CEO Paul Sabado to ask about the regulatory order, known as a consent order, but he didn’t immediately respond…
Original post:
Regulators warn Seattle’s P.I. Bank
Nanosolar hires Eugenia Corrales as new CEO
January 19, 2012
Nanosolar Inc. said Thursday it has hired Eugenia Corrales as its new CEO. The San Jose-based company’s existing CEO Geoff Tate is retiring after two years with the firm.
Read more:
Nanosolar hires Eugenia Corrales as new CEO
Velomedix raises $9.3M
December 27, 2011
Velomedix Inc. said in a regulatory filing on Monday that it has raised $9.3 million of a potential $10.7 million. The Menlo Park-based development stage medical device company specializes in therapeutic hypothermia. Its interim CEO is Jeff Gold.
Originally posted here:
Velomedix raises $9.3M
Fate Therapeutics Appoints chairman and interim CEO
December 15, 2011
San Diego headquartered biotech company Fate Therapeutics has appointed William H. Rastetter as chairman and interim CEO. Rastetter is also a partner in venture capital firm Venrock . Fate Therapeutics has secured venture backing from OVP Venture Partners , Astellas Venture Management , Genzyme Ventures , ARCH Venture Partners , Polaris Venture Partners and Venrock .
Read more:
Fate Therapeutics Appoints chairman and interim CEO
SGI CEO Mark Barrenechea resigns
December 14, 2011
Silicon Graphics International Corp.’s board of directors said Wednesday that president, CEO and board member Mark Barrenechea has tendered his resignation, effective Jan. 1, 2012. The Fremont-based company, which specializes in technical computing (NASDAQ:SGI), said the chairman of its board, Ronald Verdoorn, is expected to serve as interim CEO, as the board searches for a replacement. Barrenechea is going to work for an unspecified global enterprise software company as its president and CEO. He is expected to remain a shareholder of SGI…
See more here:
SGI CEO Mark Barrenechea resigns
Thomajan to earn $170K at United Way
December 13, 2011
Keith Thomajan will earn a base salary of $170,000 as the new president of United Way of the Columbia-Willamette. Thomajan, who starts his new job on Feb. 6, will also receive a $5,000 vehicle allowance as well as benefits. United Way declined to reveal his salary when it announced it had tapped Thomajan, longtime head of Camp Fire Columbia, to lead the organization.
Continue reading here:
Thomajan to earn $170K at United Way
